These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 27748055)

  • 1. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.
    Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
    Arthritis Rheumatol; 2017 Apr; 69(4):763-773. PubMed ID: 27748055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
    Kelly KM; Sanga P; Zaki N; Wang S; Haeussler J; Louie J; Thipphawong J
    Curr Med Res Opin; 2019 Dec; 35(12):2117-2127. PubMed ID: 31387410
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.
    Sanga P; Polverejan E; Wang S; Kelly KM; Thipphawong J
    Clin Ther; 2016 Jun; 38(6):1435-1450. PubMed ID: 27101815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial.
    Mayorga AJ; Wang S; Kelly KM; Thipphawong J
    Int J Clin Pract; 2016 Jun; 70(6):493-505. PubMed ID: 27238963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
    Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.
    Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
    Pain; 2013 Oct; 154(10):1910-1919. PubMed ID: 23748114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study.
    Wang H; Romano G; Fedgchin M; Russell L; Sanga P; Kelly KM; Frustaci ME; Thipphawong J
    Clin J Pain; 2017 Feb; 33(2):99-108. PubMed ID: 27153360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
    Lee M; Yoo J; Kim JG; Kyung HS; Bin SI; Kang SB; Choi CH; Moon YW; Kim YM; Han SB; In Y; Choi CH; Kim J; Lee BK; Cho S
    Clin Orthop Surg; 2017 Dec; 9(4):439-457. PubMed ID: 29201297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label six-month extension study to investigate the safety and efficacy of an extract of Artemisia annua for managing pain, stiffness and functional limitation associated with osteoarthritis of the hip and knee.
    Hunt S; Stebbings S; McNamara D
    N Z Med J; 2016 Oct; 129(1444):97-102. PubMed ID: 27806033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of E-OA-07 in moderate to severe symptoms of osteoarthritis: a double-blind randomized placebo-controlled study.
    Kulkarni MP; Shakeel A; Shinde BS; Rosenbloom RA
    Am J Ther; 2011; 18(2):170-7. PubMed ID: 21317618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese Medicine, for patients with osteoarthritis of the knee: a multi-site, randomized, double-blind, placebo-controlled phase II clinical trial.
    Lao L; Hochberg M; Lee DYW; Gilpin AMK; Fong HHS; Langenberg P; Chen K; Li EK; Tam LS; Berman B
    Osteoarthritis Cartilage; 2015 Dec; 23(12):2102-2108. PubMed ID: 26099553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study.
    Altman R; Hochberg M; Gibofsky A; Jaros M; Young C
    Curr Med Res Opin; 2015 Dec; 31(12):2331-43. PubMed ID: 26503347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.